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CLINICAL P ICTURE
Juvenile diabetes and visual impairment:
Wolfram syndrome
The presence of diabetes and visual impairment in a young in-
dividual is a good diagnostic criterion to suspect Wolfram syn-
drome (WS) or Diabetes insipidus, Diabetes mellitus, optic
atrophy and deafness.1,2 WS is a rare autosomal recessive dis-
ease due to mutations in the Wolframin (WFS1) gene. These
mutations lead to endoplasmic reticulum stress-related decline
of pancreatic beta-cell number and a decrease in endogenous
insulin secretion. Affected individuals are therefore usually
insulin-dependent, with a few rare exceptions reported.3–5 Here
we describe a 9-year-old boy who presented with visual impair-
ment and diabetes, with a novel homozygous WFS1 frameshift
mutation p.(Ala671fs) confirming WS. This patient has a normal
endogenous insulin level necessitating a very low total daily in-
sulin requirement for good glycaemic control.
A 9-year-old boy presented to our endocrine clinic with
decreased vision for 6 months and polyuria for 4 months. His
parents were non-consanguineous and there was no family his-
tory of diabetes. His visual acuity was 1/6 on both eyes and ret-
inal examination revealed bilateral optic atrophy without
diabetic retinopathy (Figure 1A and B). His fasting blood glucose
levels were elevated at 14.43 mmol/l with no ketonuria and
HbA1C of 9.2%. Anti-glutamic acid decarboxylase antibody lev-
els were normal with a normal c-peptide. An audiogram and an
abdomen ultrasound were normal and there were no learning
difficulties. An overnight water deprivation test was normal. In
view of the optic atrophy and juvenile diabetes a genetic ana-
lysis was done to confirm WS. Sanger sequencing analysis of
the WFS1 gene (NM_006005.3) detected a homozygous frame-
shift mutation p.(Ala671fs), c.2010dup, in the last exon. This
variant is predicted to result in insertion of a premature termin-
ation codon after 41 amino acids, resulting in possible transla-
tion of a truncated protein and loss of >10% of the normal WFS1
protein. The patient’s parents were both heterozygous for the
mutation. The patient was treated with small doses of insulin
with remarkable glycaemic and visual improvement. He is cur-
rently requiring five units of biphasic insulin daily for the past
24 months with an HbA1c of 6% and no further neuro-
degenerative progression.
WS is a neuro-degenerative disorder due to mutations in the
WFS1 gene leading to non-autoimmune insulin-deficient dia-
betes mellitus. Due to the variable presentation there is no diag-
nostic marker available for this syndrome and, as in our case,
juvenile diabetes with optic atrophy remain the best available
clinical diagnostic criteria, even in the absence of other neuro-
degenerative features.1,2 However, partial phenotypes in the ab-
sence of diabetes and optic atrophy have been previously
described.6 A possible genotype–phenotype relationship has
been suggested, which could have implications for early diagno-
sis and management. Diabetic ketoacidosis and microvascular
complications are seen less frequently in individuals with WS
Figure 1. (A) Right eye retinal images showing optic atrophy without retinopathy. (B) Left eye retinal images showing optic atrophy without retinopathy.
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than Type 1 diabetes.5 Although it is common to have insulin defi-
ciency, there have been a few reports similar to our case docu-
menting an intact pancreatic reserve with normal c-peptide levels
and very low insulin requirements.3–5 Early identification with
good glycaemic control in individuals with WS has been found to
slow the progression of neuro-degenerative symptoms.4 An asso-
ciation was found between HbA1c levels and neuro-degenerative
syndromes and endocrine symptoms inWS.4 Our patient is young
and hence could progressively develop additional neurological
features of WS later in life. However, poor glycaemic control and
chronic hyperglycaemia is associated with a quicker progression
of WS.4 Our patient and larger series of subjects with WS need to
be regularly monitored and followed up to promptly recognise
progression, and confirm whether good glycaemic control results
in a slower progression and better prognosis.
This case highlights the need for an increased vigilance to-
wards early identification, genetic testing and treatment of WS
in a young individual with visual symptoms and diabetes irre-
spective of the endogenous insulin reserve. A strict glycaemic
control with a lower HbA1c target at follow up warrants a better
quality of life with a slow progression of WS. Our case also illus-
trates the possible partial phenotypic presentation of this dis-
order confirming the variable spectrum of features at the time
of presentation.
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